Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of TAS-115 in idiopathic pulmonary fibrosis
jRCT2080223842Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamufetinib in idiopathic pulmonary fibrosis (IPF), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Change in %FVC decline. Started Mar 2018; status: completed.
02
Drugs
pamufetinib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2080223842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223842.